S-217622

Shionogi's SCORPIO-PEP Phase 3 trial demonstrated ensitrelvir reduces COVID-19 risk by 67% in exposed household contacts, making it the first oral antiviral to successfully prevent COVID-19 after exposure.

The SCORPIO-PEP international trial found that ensitrelvir reduced COVID-19 infection risk by 67% in household contacts when administered within 72 hours of exposure.

The Conference on Retroviruses and Opportunistic Infections (CROI) 2025 will convene in San Francisco from March 9-12, featuring cutting-edge research on HIV cure strategies, COVID-19 variants, and viral infections.

Ildong Pharmaceutical will resubmit its application for Ensitrelvir, an oral antiviral drug for COVID-19, after strengthening clinical data.

The FDA is creating a more accessible regulatory environment for cell and gene therapy companies, according to executives at BioFuture 2024.